A close look at how Merck is navigating Q1 2026 momentum, the looming Keytruda 2028 loss of exclusivity, and a reshaped pipeline anchored by Winrevair, Verona Pharma's Ohtuvayre, and the Daiichi Sankyo ADC alliance.

Key Highlights

  • Merck reported Q1 2026 Revenue of roughly $16.29 billion, up about 4.9% year over year, beating Wall Street consensus and prompting a narrowed and slightly raised 2026 outlook.
  • Keytruda remains the Franchise anchor, but management is actively pushing the subcutaneous Keytruda Qlex formulation, approved in September 2025, to defend Revenue ahead of the 2028 Patent cliff.
  • The $10 billion Verona Pharma Acquisition, completed in October 2025, brings COPD drug Ohtuvayre into the cardio-pulmonary portfolio alongside Winrevair, which posted $525 million in Q1 2026 sales (up 88% year over year).
  • Gardasil sales remain pressured, with China Demand stepping down sharply in 2025 and Merck withdrawing its prior $11 billion 2030 sales target.
  • MRK trades at a P/E in the mid-teens with a Dividend-yield/">Dividend Yield near 3%, and the analyst consensus sits at Buy with a 12-month price target around $123.

 

Few names in large-cap pharmaceuticals draw as much attention right now as Merck & Co., Inc. (NYSE:MRK). The stock is in focus because the company just delivered a Q1 2026 Earnings beat, narrowed its full-year guidance higher, and continues to lay the groundwork for life after Keytruda's 2028 loss of exclusivity. Investors are weighing strong execution on newer launches against well-known headwinds in China and the eventual reset that biosimilar competition will bring. With shares trading in a tight range and a high-single-digit forward Earnings multiple by sector standards, MRK has become a core watchlist name for both income-seeking and growth-oriented investors evaluating large pharma in 2026.

Company Overview

Merck & Co., Inc. is a global biopharmaceutical company headquartered in Rahway, New Jersey, and known internationally as MSD outside the United States and Canada. The company operates across two main reporting segments: Pharmaceutical, which includes oncology, vaccines, immunology, cardiovascular, virology, and neuroscience products, and Animal Health, which markets products for livestock and companion animals.

The pharmaceutical portfolio leans heavily on a handful of marquee Assets: Keytruda (pembrolizumab) in oncology, Gardasil/Gardasil 9 in vaccines, Lagevrio in antivirals, Bridion in anesthesia Reversal, and a fast-growing cardio-pulmonary group led by Winrevair (sotatercept-csrk) and now Ohtuvayre (ensifentrine). Merck Animal Health, while smaller, provides Revenue Diversification and steady cash generation.

For investors, the story is simple to summarize and harder to handicap. Keytruda has been one of the most successful drugs in pharmaceutical history, generating roughly $31.7 billion in 2025 sales. The strategic question is what fills the gap as that asset transitions to biosimilar competition starting around 2028.

Latest News Catalyst

The most recent catalyst is Merck's Q1 2026 Earnings release on April 30, 2026. The company beat on both top and Bottom Line, raised the low end of its 2026 Revenue guidance to a range of $65.8 billion to $67 billion, and lifted its adjusted EPS outlook to a range of $5.04 to $5.16. Shares responded positively in pre-market and intraday action.

Beyond Earnings, two non-quarterly events continue to shape the narrative. First, the FDA's September 2025 approval of subcutaneous Keytruda (Keytruda Qlex) created a defensive playbook against the 2028 intravenous Patent expiration. Second, Merck closed its $10 billion Acquisition of Verona Pharma in October 2025, adding Ohtuvayre, the first novel inhaled COPD maintenance mechanism in more than 20 years. Both moves target the question that defines MRK as an Investment case: how does the company replace Keytruda Revenue?

Recent Earnings

The Q1 2026 print told a balanced story. Revenue of approximately $16.29 billion grew 4.9% year over year. Keytruda continued to lead, with consensus estimates pointing to roughly $7.73 billion in quarterly sales, up about 7.3% year over year. Winrevair contributed $525 million, up 88% from the prior-year quarter, reflecting both continued U.S. uptake and early international launches.

Management's narrowed and slightly higher 2026 guidance suggests confidence in second-half performance, even as Gardasil headwinds in China persist. The Earnings beat lifted shares, but the broader market focus quickly returned to the long-running question about Earnings durability beyond 2028.

For comparison, full-year 2025 saw Keytruda Revenue of about $31.7 billion (up 7%), while Gardasil sales fell from $8.6 billion in 2024 to roughly $5.2 billion in 2025, a drop of nearly 39%. Investors may want to watch whether Q2 2026 commentary points to any stabilization in Chinese HPV Demand or continued weakness.

Stock Price Reaction and Market Sentiment

MRK shares have been range-bound for much of the past year as investors process the dual narrative of strong in-line execution and looming Patent risk. As of late April 2026, the stock has been trading in the $110 to $114 area, with a market Capitalization in the high $200 billion range.

Sentiment is best described as cautiously constructive. Among the roughly 25 to 27 analysts covering the name, the majority carry Buy ratings, with a smaller cohort at Hold and only a single Sell. The consensus 12-month price target sits near $123.81, implying mid-teens upside from recent levels before factoring in the Dividend.

Options market positioning around Earnings has reflected modest expected moves, suggesting that the Buy-Side broadly views Keytruda's near-term durability as well-understood and the Patent cliff as a 2028 problem rather than a 2026 problem. The market reaction to the Q1 2026 beat reinforced that view.

Key Growth Drivers

Several drivers underpin the bull thesis on Merck.

Subcutaneous Keytruda (Keytruda Qlex). The September 2025 FDA approval of a subcutaneous formulation gives Merck a route to convert a significant portion of patients to a method of administration that is less time-intensive than the standard 30-minute IV infusion. CEO Rob Davis has indicated the subcutaneous version could capture 30% to 40% of the U.S. Keytruda patient base by 2027. Importantly, the new formulation carries fresh Patent protection, with method-of-treatment and Manufacturing claims that could extend exclusivity well beyond 2028.

Winrevair Franchise expansion. Sales reached $976 million through the first nine months of 2025 and $525 million in Q1 2026 alone. Analyst peak sales estimates cluster around $8 billion to $8.5 billion annually, with potential expansion into heart failure with preserved ejection fraction (HFpEF) on top of pulmonary arterial hypertension (PAH).

Ohtuvayre (Verona Pharma Acquisition). Ohtuvayre is described as the first novel inhaled COPD maintenance mechanism in more than two decades. The $10 billion deal price implies meaningful Revenue expectations from this single asset over the next decade.

Daiichi Sankyo ADC alliance. The 2023 collaboration brings three antibody-drug conjugates under joint development, including ifinatamab deruxtecan (I-DXd), which has been granted FDA Priority Review for previously treated extensive-stage small cell lung cancer with a PDUFA date of October 10, 2026. Patritumab deruxtecan and raludotatug deruxtecan round out the Partnership, with potential total deal value up to $22 billion.

Animal Health and vaccines. While Gardasil has stumbled, the underlying Animal Health Business and other vaccines provide Diversification and lower-Volatility Cash Flow.

Main Risks Investors Should Watch

The risk side of the ledger is well-known but remains material.

Keytruda 2028 loss of exclusivity. Without successful conversion to subcutaneous and continued label expansion, Merck faces an estimated 80% Revenue erosion on its flagship product post-2028. Even with mitigation strategies, biosimilar competition will pressure margins.

Gardasil China overhang. China accounted for roughly 60% to 70% of Gardasil's overseas sales. A domestically produced nine-valent HPV Vaccine priced at roughly $70 per dose, a 60% discount to Gardasil 9, has reset competitive Economics. Merck has paused shipments at points and dropped its prior $11 billion 2030 target.

Pipeline execution risk. The Daiichi ADC program has experienced clinical setbacks, including a partial trial hold tied to patient deaths. ADCs are a high-reward but unforgiving therapeutic class.

M&A integration risk. Verona is now part of Merck, but realizing the COPD growth thesis depends on commercial execution against entrenched competitors.

Policy risk. Drug pricing legislation in the U.S., changes to international reference pricing, and ongoing IRA-related Medicare negotiation lists remain background risk factors for all large-cap pharma names.

Valuation Discussion

MRK trades at a forward P/E in the mid-teens, modestly below the broader healthcare sector average. The discount reflects the Patent cliff overhang more than current Earnings power. The Dividend-yield/">Dividend Yield sits near 3%, with an annual Dividend of $3.40 per share, paid quarterly, supported by strong free Cash Flow generation.

On an EV/EBITDA basis, Merck looks reasonable relative to large-cap pharma peers, though direct comparisons are complicated by varying Patent timelines and pipeline mixes. Investors evaluating valuation may want to consider scenario analysis: a base case where subcutaneous Keytruda and Winrevair offset roughly half of IV Keytruda erosion, a bull case where they offset more, and a bear case where biosimilar pressure exceeds current models.

Free Cash Flow continues to fund dividends, share repurchases, and bolt-on M&A. The Verona deal demonstrates management's willingness to deploy Capital aggressively when an asset fits the strategic gap.

Bull Case

The bull case for Merck rests on management successfully extending Keytruda's Franchise life through the subcutaneous formulation and on the new growth pillars scaling faster than current consensus models. If Keytruda Qlex captures the upper end of the 30% to 40% conversion range, Merck preserves a substantial portion of high-Margin oncology Revenue. Layer on Winrevair reaching $8 billion-plus in peak sales, Ohtuvayre delivering on its first-in-class COPD mechanism, and the Daiichi ADC platform producing additional approvals, and Merck's growth profile in the early 2030s could surprise to the upside.

A re-rating in the multiple is also possible if investors gain confidence that the Patent cliff has been largely defused. In that scenario, mid-teens P/E expansion to high-teens combined with mid-single-digit EPS growth could produce attractive total returns. Risk-tolerant investors may be paying attention to the optionality embedded in the pipeline, particularly in oncology and cardio-pulmonary.

Bear Case

The bear case starts with the math of the 2028 cliff. Even with subcutaneous conversion, biosimilar IV Keytruda will pressure pricing on the dominant administration form. If conversion lags expectations or if payors restrict the subcutaneous product, the Revenue erosion could reach the upper end of the 80% scenario.

Gardasil dynamics add to the concern. The China step-down may not reverse, and even ex-China growth may not fully replace lost Demand. Pipeline disappointments in the Daiichi ADC Franchise or slower-than-expected Winrevair indication expansion would weaken the offset story.

In a bear scenario, MRK becomes a Dividend stock with limited multiple expansion, potentially trading at a low-double-digit P/E for several years until the next-generation portfolio reasserts itself. The Dividend-yield/">Dividend Yield offers some downside cushion, but Capital appreciation may be limited.

Investor Takeaways

  • The Q1 2026 beat and narrowed guidance affirm near-term execution, but the long-term thesis still pivots on the 2028 transition.
  • Subcutaneous Keytruda is the single most important strategic lever for Merck over the next 24 months.
  • Winrevair, Ohtuvayre, and the Daiichi ADC program represent the most credible Diversification efforts in years.
  • Gardasil headwinds in China are likely to persist and should be modeled accordingly.
  • A roughly 3% Dividend-yield/">Dividend Yield, mid-teens valuation, and Buy consensus rating make MRK a core large-cap pharma watchlist name, with risk-tolerant investors monitoring pipeline catalysts most closely.

Conclusion

The Merck stock analysis 2026 picture is a balance of strong execution today against well-defined structural challenges tomorrow. Q1 2026 confirmed that Keytruda continues to deliver, Winrevair is scaling rapidly, and the company has the Capital and willingness to make sizeable strategic moves like the Verona Pharma Acquisition. At the same time, the 2028 Keytruda cliff and persistent Gardasil weakness in China remain unresolved variables that will define long-term returns.

For investors building a view on MRK, the key questions are whether subcutaneous Keytruda meaningfully blunts biosimilar erosion, whether Winrevair and Ohtuvayre can together approach blockbuster scale, and whether the Daiichi Sankyo ADC Partnership produces a next wave of oncology growth. With a Buy-leaning analyst consensus, a near-3% Dividend-yield/">Dividend Yield, and a valuation that already reflects much of the Patent cliff concern, Merck remains one of the most closely watched large-cap pharma names in 2026. Investors may want to watch upcoming pipeline catalysts and the next several quarters of subcutaneous Keytruda conversion data to gauge how the long-term thesis is tracking.